Sage Journals: Discover world-class research

Abstract

Endothelin (ET)-1_1–21 is known to play an important role in the pathogenesis of acute ischemic arrhythmia. In the present study, we attempted to determine whether administration of ET-1_1–31 would result in arrhythmia in perfused isolated rat hearts. Forty-eight Sprague-Dawley rats weighing ~250–350 g were randomized into 6 groups. Heart was isolated and perfused in a Langendorff mode. The effects of ET-1_1–31 on arrhythmia, heart rate, coronary flow, and heart function were analyzed. Perfusion with 1 nM ET-1_1–31 resulted in frequent ventricular ectopic beats (VEBs) and ventricular tachycardia (VT). Overall VEB was 128.0 (~66.0–1015.0), and the arrhythmia score (AS) was 2.18 ± 0.87; both were significantly higher than those of the control group (P < 0.01). Pretreatment with perfusion of 10 nM of the ETA-receptor antagonist BQ₁₂₃ markedly attenuated the occurrence of VEB and VT induced by ET-1_1–31. AS in 10 nM BQ₁₂₃ group was significantly lower than that in 1 nM ET-1_1–31 group (P < 0.01). The arrhythmia induced by 1 nM ET-1_1–31 was partially but significantly reduced by phosphoramidon (1 μM), a neutral endopeptidase/ET-converting enzyme inhibitor. ET-1_1–31 per se caused arrhythmia in perfused isolated rat hearts. This arrhythmogenic action is in part mediated by ET_A receptor and may be attributed mainly to the conversion of ET-1_1–31 to ET-1_1–21.

Get full access to this article

View all access options for this article.

References

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415, 1988.

Goto K, Hama H, Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol 72:261–290, 1996.

Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 159:1987–1992, 1997.

Yoshizumi M, Inui D, Okishima N, Houchi H, Tsuchiya K, Wakabayashi H, Kido H, Tamaki T. Endothelin-1-(1–31), a novel vasoactive peptide, increases [Ca²⁺ ]i in human coronary artery smooth muscle cells. Eur J Pharmacol 348:305–309, 1998.

Yasuoka H, Yoshizumi M, Inui D, Okishima N, Houchi H, Kirima K, Oshita S, Kido H, Tamaki T. Effect of endothelin-1(1–31) on intracellular free calcium in cultured human mesangial cells. Life Sci 65:PL267– PL272, 1999.

Hayasaki-Kajiwara Y, Naya N, Shimamura T, Iwasaki T, Nakajima M. Endothelin generating pathway through endothelin1–31 in human cultured bronchial smooth muscle cells. Br J Pharmacol 127:1415–1421, 1999.

Watts SW, Fink GD, Northcott CA, Galligan JJ. Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists. Br J Pharmacol 137:69–79, 2002.

Saijo Y, Maeda K, Nakaya Y, Kamada M, Mitani R, Endo S, Irahara M, Yamano S, Anono T. Altered sensitivity to a novel vasoconstrictor endothelin-1 (1–31) in myometrium and umbilical artery of women with severe preeclampsia. Biochem Biophys Res Commun 286:964–967, 2001.

Yoshizumi M, Kim S, Kagami S, Hamaguchi A, Tsuchiya K, Houchi H, Iwao H, Kido H, Tamaki T. Effect of endothelin-1 (1–31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Br J Pharmacol 125:1019–1027, 1998.

10.

Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K, Suzaki Y, Abe S, Hasegawa T, Tamaki T. Antioxidants inhibit endothelin-1 (1–31)-induced proliferation of vascular smooth muscle cells via the inhibition of mitogen-activated protein (MAP) kinase and activator protein-1 (AP-1). Biochem Pharmacol 64:1521–1531, 2002.

11.

Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DWI. The Lambeth Conventions: guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res 22:447–455, 1988.

12.

Johnston KM, MacLeod BA, Walker MJ. Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmics. Can J Physiol Parmacol 61:1340–1353, 1983.

13.

Garjani A, Wainwright CL, Zeitlin IJ, Wilson C, Slee SJ. Effects of endothelin-1 and the ETA-receptor antagonist, BQ123, on ischemic arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 25:634–642, 1995.

14.

Sharif I, Kane KA, Wainwright CL. Endothelin and ischaemic arrhythmias-antiarrhythmic or arrhythmogenic. Cardiovasc Res 39: 625–632, 1998.

15.

Lin L, Yuan W-J. Effects of different preproendothelin-1 mRNA anti-sense oligodeoxynucleotides on ischemic arrhythmias in rats. J Cardiovasc Pharmacol 39:590–599, 2002.

16.

Yuan W-J, Qiu J-W, Lin L, Pan X-J, Ren A-J, Chen H, Tang C-S. Effects of endothelin-1 mRNA antisense oligodeoxynucleotides on ischemic arrhythmia in isolated rat hearts. Drug Dev Res 58:138–144, 2003.

Arrhythmogenic Action of Endothelin-1 1–31 Through Conversion to Endothelin-1 1–21

Abstract

Get full access to this article

References